Glyburide drug classification
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Glyburide Drug Classification
Introduction to Glyburide: Second-Generation Sulfonylurea
Glyburide, also known as glibenclamide, is classified as a second-generation sulfonylurea hypoglycemic agent. It is significantly more potent than first-generation sulfonylureas, such as tolbutamide, due to its greater intrinsic hypoglycemic potency rather than a prolonged biological half-life. This medication is primarily used to manage non-insulin-dependent diabetes mellitus (NIDDM), also known as type 2 diabetes.
Mechanism of Action: Insulin Secretion and Sensitization
Glyburide functions by stimulating pancreatic insulin secretion and decreasing insulin resistance in muscle and liver tissues. This dual mechanism makes it effective in reducing blood glucose levels in patients whose hyperglycemia is not adequately controlled by diet and exercise alone . Additionally, glyburide has a unique feature of prolonged activity despite a short half-life, which contributes to its effectiveness in lower doses compared to first-generation sulfonylureas.
Metabolism and Excretion
Glyburide is metabolized in the liver to 4-trans-hydroxyglyburide and 3-cis-hydroxyglyburide, with approximately 50% of these metabolites excreted in the urine and 50% in the bile. Unlike older sulfonylureas, about half of glyburide is excreted through feces, which may contribute to its lower frequency of adverse effects.
Clinical Efficacy and Safety
Comparison with Other Hypoglycemic Agents
Studies have shown that glyburide is at least as effective as first-generation sulfonylureas and other oral hypoglycemic agents like metformin. In a randomized controlled study comparing glyburide and metformin for the treatment of gestational diabetes mellitus (GDM), both drugs demonstrated comparable efficacy in glucose control and adverse effects. Another study comparing glyburide with insulin in women with GDM found glyburide to be a clinically effective alternative to insulin therapy, with no significant differences in maternal and neonatal complications.
Combination Therapy
Glyburide is also effective when used in combination with other hypoglycemic agents. For instance, a study comparing glyburide/metformin combination therapy with monotherapy found that the combination provided superior glycemic control, allowing more patients to achieve treatment goals with lower doses of each component.
Adverse Effects and Precautions
While glyburide is generally well-tolerated, it can cause hypoglycemic episodes, particularly in elderly patients or those with liver or significant renal disease. Therefore, it should be prescribed in small initial doses and with caution in these populations . The drug has a lower frequency of adverse effects compared to first-generation sulfonylureas and has not shown significant drug interactions or toxic reactions in long-term use.
Conclusion
Glyburide is a potent and effective second-generation sulfonylurea hypoglycemic agent used primarily for the management of type 2 diabetes. Its ability to stimulate insulin secretion and decrease insulin resistance, combined with its favorable safety profile, makes it a valuable option for patients whose hyperglycemia is not adequately controlled by diet and exercise alone.
Sources and full results
Most relevant research papers on this topic